Mico BioMed Co. Ltd. (214610) - Net Assets
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) has net assets worth ₩25.81 Billion KRW (≈ $17.49 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩33.69 Billion ≈ $22.83 Million USD) and total liabilities (₩7.88 Billion ≈ $5.34 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mico BioMed Co. Ltd. (214610) strategic investment index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩25.81 Billion |
| % of Total Assets | 76.6% |
| Annual Growth Rate | 20.31% |
| 5-Year Change | -53.74% |
| 10-Year Change | N/A |
| Growth Volatility | 1694.23 |
Mico BioMed Co. Ltd. - Net Assets Trend (2015–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Mico BioMed Co. Ltd..
Annual Net Assets for Mico BioMed Co. Ltd. (2015–2024)
The table below shows the annual net assets of Mico BioMed Co. Ltd. from 2015 to 2024. Also explore 214610 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩25.89 Billion ≈ $17.54 Million |
-28.75% |
| 2023-12-31 | ₩36.33 Billion ≈ $24.62 Million |
+105.33% |
| 2022-12-31 | ₩17.69 Billion ≈ $11.99 Million |
-66.14% |
| 2021-12-31 | ₩52.26 Billion ≈ $35.42 Million |
-6.62% |
| 2020-12-31 | ₩55.96 Billion ≈ $37.92 Million |
+5382.60% |
| 2019-12-31 | ₩1.02 Billion ≈ $691.72K |
-82.13% |
| 2018-12-31 | ₩5.71 Billion ≈ $3.87 Million |
+67.09% |
| 2017-12-31 | ₩3.42 Billion ≈ $2.32 Million |
-10.63% |
| 2016-12-31 | ₩3.83 Billion ≈ $2.59 Million |
-21.96% |
| 2015-12-31 | ₩4.90 Billion ≈ $3.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mico BioMed Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13770915900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩25.75 Billion | 99.49% |
| Other Components | ₩162.82 Billion | 629.03% |
| Total Equity | ₩25.89 Billion | 100.00% |
Mico BioMed Co. Ltd. Competitors by Market Cap
The table below lists competitors of Mico BioMed Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Callan JMB Inc. Common Stock
NASDAQ:CJMB
|
$13.00 Million |
|
Orissa Bengal Carrier Limited
NSE:OBCL
|
$13.00 Million |
|
Wegmans Holdings Berhad
KLSE:0197
|
$13.00 Million |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
$13.01 Million |
|
Forgame Holdings Limited
F:FH0
|
$12.99 Million |
|
Tomypak Holdings Bhd
KLSE:7285
|
$12.99 Million |
|
Embelton Ltd
AU:EMB
|
$12.98 Million |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
$12.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mico BioMed Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 36,980,786,560 to 25,885,135,400, a change of -11,095,651,160 (-30.0%).
- Net loss of 29,931,396,720 reduced equity.
- Share repurchases of 10,978,273,040 reduced equity.
- New share issuances of 10,978,273,040 increased equity.
- Other factors increased equity by 18,835,745,560.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-29.93 Billion | -115.63% |
| Share Repurchases | ₩10.98 Billion | -42.41% |
| Share Issuances | ₩10.98 Billion | +42.41% |
| Other Changes | ₩18.84 Billion | +72.77% |
| Total Change | ₩- | -30.00% |
Book Value vs Market Value Analysis
This analysis compares Mico BioMed Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.46x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.40x to 0.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩953.35 | ₩2290.00 | x |
| 2017-12-31 | ₩375.77 | ₩2290.00 | x |
| 2018-12-31 | ₩498.55 | ₩2290.00 | x |
| 2019-12-31 | ₩78.71 | ₩2290.00 | x |
| 2020-12-31 | ₩3083.94 | ₩2290.00 | x |
| 2021-12-31 | ₩2200.86 | ₩2290.00 | x |
| 2022-12-31 | ₩744.60 | ₩2290.00 | x |
| 2023-12-31 | ₩848.88 | ₩2290.00 | x |
| 2024-12-31 | ₩5026.60 | ₩2290.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mico BioMed Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -115.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -645.06%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 2.10x
- Recent ROE (-115.63%) is above the historical average (-280.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -125.48% | -298.48% | 0.17x | 2.48x | ₩-5.18 Billion |
| 2017 | -380.31% | -439.44% | 0.18x | 4.81x | ₩-13.34 Billion |
| 2018 | -153.17% | -244.05% | 0.15x | 4.23x | ₩-9.32 Billion |
| 2019 | -1433.47% | -357.04% | 0.16x | 24.52x | ₩-14.73 Billion |
| 2020 | -10.32% | -12.65% | 0.64x | 1.27x | ₩-11.37 Billion |
| 2021 | -20.24% | -34.90% | 0.34x | 1.70x | ₩-15.80 Billion |
| 2022 | -219.82% | -241.40% | 0.28x | 3.25x | ₩-40.66 Billion |
| 2023 | -69.70% | -480.20% | 0.09x | 1.66x | ₩-29.47 Billion |
| 2024 | -115.63% | -645.06% | 0.09x | 2.10x | ₩-32.52 Billion |
Industry Comparison
This section compares Mico BioMed Co. Ltd.'s net assets metrics with peer companies in the Publishing industry.
Industry Context
- Industry: Publishing
- Average net assets among peers: $100,233,604,894
- Average return on equity (ROE) among peers: -0.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mico BioMed Co. Ltd. (214610) | ₩25.81 Billion | -125.48% | 0.31x | $13.00 Million |
| WFM Inc. (035290) | $14.55 Billion | -42.98% | 0.29x | $1.24 Million |
| YeaRimDang Publishing Co. Ltd (036000) | $108.39 Billion | 18.09% | 2.39x | $43.55 Million |
| Samsung Publis (068290) | $73.48 Billion | 5.17% | 0.18x | $42.22 Million |
| Woongjin Thinkbig Co Ltd (095720) | $321.06 Billion | -9.63% | 1.30x | $45.82 Million |
| Visang Educati (100220) | $138.58 Billion | 12.25% | 0.54x | $41.60 Million |
| e-future.Co.Ltd (134060) | $21.66 Billion | 13.20% | 0.13x | $13.63 Million |
| Mr. Blue Corporation (207760) | $55.62 Billion | -20.18% | 1.07x | $118.92 Million |
| D&C Media Co.Ltd (263720) | $68.53 Billion | 22.04% | 0.29x | $60.06 Million |
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more